Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Claritin Clear all
Not listed Phase 2 Interventional

Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain

NCT01311336
View directory record Official record
Conditions
Pegfilgrastim-induced Back and Leg Pain
Interventions
Loratadine, placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Brewer, Maine • Scarborough, Maine • York Village, Maine + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Patient Experience Study of Deoxycholic Acid Injection

NCT02007434
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
Drug · Other
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

NCT06019728
View directory record Official record
Conditions
Fabry's Disease
Interventions
AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine, Dexamethasone, Montelukast, Loratadine, Cetirizine, Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Santa Monica, California • Atlanta, Georgia • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 2, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional Results available

Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement

NCT00895531
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
Depodur, sciatic nerve block
Drug · Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects

NCT03517930
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 2, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional Results available

Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

NCT03883386
View directory record Official record
Conditions
Bone Pain
Interventions
Loratadine, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
12 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 2, 2026, 8:02 AM EDT
Recruiting Phase 4 Interventional

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

NCT07101445
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Acetaminophen, Biospecimen Collection, Dexamethasone, Electronic Health Record Review, Famotidine, Loratadine, Methylprednisolone, Montelukast, Motixafortide, Pheresis, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor
Drug · Procedure · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

NCT05265910
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale, Placebo
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

NCT03517943
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

NOLAN: Naproxen or Loratadine and Neulasta

NCT01712009
View directory record Official record
Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
83
States / cities
Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 2, 2026, 8:02 AM EDT
Terminated Early Phase 1 Interventional

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

NCT02392039
View directory record Official record
Conditions
Lymphoma
Interventions
Pegfilgrastim, Loratadine, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

NCT00449072
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Placebo, TAA-AQ, Nasacort® AQ, Claritin®
Other · Drug
Lead sponsor
Sanofi
Industry
Eligibility
3 Years to 9 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Efficacy of Claritin in Healthy Subjects

NCT01451996
View directory record Official record
Conditions
Healthy
Interventions
Claritin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 2, 2026, 8:02 AM EDT
Recruiting Phase 2 Interventional

Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

NCT07661459
View directory record Official record
Conditions
Solid Tumors
Interventions
Asprin, Loratadine, Acetaminophen Avoidance, THC Avoidance
Drug · Behavioral
Lead sponsor
Val Adams
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 8:02 AM EDT
Completed No phase listed Observational

Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

NCT02305979
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Loratadine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 2, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional Results available

Antihistamines in Eosinophilic Esophagitis

NCT04248712
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Famotidine, Loratadine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

NCT06955741
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BMS-986446 IV, BMS-986446 SC, Acetaminophen, Loratadine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 8:02 AM EDT
Recruiting Early Phase 1 Interventional

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

NCT04211259
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Loratadine, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 2, 2026, 8:02 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

NCT05263206
View directory record Official record
Conditions
Pruritus
Interventions
Dupilumab, Placebo, Fexofenadine (loratadine if not available)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 90 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Bakersfield, California • La Jolla, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies

NCT04162795
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Loratadine (Claritin, BAY76-2211)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 2, 2026, 8:02 AM EDT